Technology
Choose a subcategory:
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2010 Financial Results on Tu
Transition Therapeutics Inc. Dr. Tony Cruz, Chief Executive Officer 416-260- 7770, x. 223 tcruz@ transitiontherapeutics. com Mr. Elie Farah, President and CFO 416-260- 7770, x. 203 efarah@ transitiontherapeutics. com
Operational highlights since the beginning of the quarter include:- U.S. cardiac regeneration program:- U.S. Phase II IMPACT-DCM clinical trial ( surgical delivery)- To date, this clinical trial has enrolled 29 patients at five sites across
Key developments this quarter and future planned activities: Epratuzumab* UCB is expected to initiate Phase III clinical trial programs, after end-of-Phase IIb data presentation and consultation with regulatory authorities in the United Sta
BUFFALO, N.Y., Nov. 6, 2009 ( GLOBE NEWSWIRE)- Rand Capital Corporation ( " Rand"), a business development company ( BDC) that provides capital and managerial expertise for small to medium-sized private companies, announced that it has inve
The strategy is supported by results from XOMA 052 Phase 1 trials demonstrating improvement in biomarkers associated with cardiovascular risk, ongoing clinical trials in cardiovascular disease with other IL-1 targeted agents, animal studies
( ACHN) Statements of Operations ( Unaudited, in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2009 2008 2009 2008 Revenue $ ( 54) $ 25 $ ( 355) $ 1,050 Operating expenses: Research an
HAMBURG, Germany, Nov. 6, 2009 ( GLOBE NEWSWIRE)- Evotec AG ( TecDAX) will report its financial results for the third quarter of 2009 on Thursday, 12 November 2009.
AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS ( UNAUDITED) As of As of September 30, March 31, 2009 2009 ( in thousands) ASSETS Cash and cash equivalents $ 88,343 $ 107,788 Accounts receivable, net of allowance for doubtful 93,317
Nanosphere, Inc. Statements of Operations ( Unaudited) Three Month Periods Nine Month Periods Ended September 30, Ended September 30, 2009 2008 2009 2008 REVENUE: Grant and contract revenue $ 422,300 $ 73,459 $ 581,797 $ 346,071 Product sal
Nabi Biopharmaceuticals CONDENSED CONSOLIDATED BALANCE SHEETS ( Unaudited) ( In thousands) December 27, September 26, 2008 2009 ( as adjusted) ASSETS Current assets: Cash and cash equivalents $ 28,148 $ 106,438 Marketable securities 75,145
Neptune Technologies & Bioressources Inc. Reports on Active Pharmaceutical Ingredient (API) Preclini
Neptune Technologies & Bioressources Inc. Henri Harland, CEO 450-687- 2262 h. harland@ neptunebiotech. com www.neptunebiotech. com Acasti Pharma Inc. Dr. Tina Sampalis, President 450-687- 2262 t. sampalis@ acastipharma. com www.acastipharma
Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studie